TSX Venture: QPT
EDMONTON, July 31, 2012 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT)
("Quest" or the "Company"), a pharmaceutical company developing and
commercializing products for the treatment of cancer, announces that
all of the resolutions proposed at its Annual General and Special
Meeting of Shareholders held on July 26, 2012 were duly passed.
In addition to the re-election of four directors, shareholders also have
approved the Investment Financing Arrangement, the Creation of a
Control Person and changes to the Company's stock option plan.
Approximately 25,600,000 shares were voted for the meeting representing
31% of the Company's outstanding shares.
About Quest PharmaTech Inc.
Quest is a publicly traded, Alberta-based biotechnology company
committed to the development and commercialization of oncology product
candidates. It is developing a series of products for the treatment of
cancer based on its pipeline of SonoLight compounds; and monoclonal
antibodies which target certain tumour antigens that are presented in a
variety of cancers.
Quest believes that combinatorial immunotherapy, which exploits the
immune modulating effects of selected cytotoxic agents normally used in
standard chemotherapy regimens along with specific immune stimulants
will lead to important commercial applications of the Company's
proprietary platform. Quest is currently conducting two carefully
planned, risk mitigating confirmatory phase II clinical trials with
oregovomab, not only to validate the superiority of the combinatorial
approach, but also to design a definitive product registration study
for the treatment of ovarian cancer. The Company's MUC1 antibody
program has the potential to permit tumour specific immunization to a
broad range of additional cancers, including colon, non small cell
lung, breast and pancreas. Quest is also conducting a phase I clinical
trial for the treatment of prostate cancer, with its SonoLight
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Quest PharmaTech Inc.
For further information:
Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: firstname.lastname@example.org, Internet: www.questpharmatech.com.